Adamas Wins Parkinson’s Drug Approval, Genmab Soars, Amgen Defends PCSK9 Price

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.